Haemagglutination-inhibiting antibody to influenza virus
- PMID: 15088777
Haemagglutination-inhibiting antibody to influenza virus
Abstract
The results of the haemagglutination-inhibiting (HI) antibody test for influenza virus antibody in human sera closely match those produced by virus neutralization assays and are predictive of protection. On the basis of the data derived from 12 publications concerning healthy adults, we estimated the median HI titre protecting 50% of the vaccinees against the virus concerned at 28. This finding supports the current policy requiring vaccines to induce serum HI titres of > or = 40 to the vaccine viruses in the majority of the vaccinees. Unfortunately similar studies are scanty for the elderly, the group most at risk of influenza. There still remain many unsolved technical problems with the HI assay and we recommend that these problems be studied and the virus neutralization test as a predictor of resistance to influenza be assessed. Although the studies on this issue often give conflicting results, they generally show that HI antibody responses to influenza vaccination tend to diminish with increasing age, when health is often compromized. Advanced age in itself seems not to be an independent factor in this process. However, even in completely healthy elderly individuals the response to vaccination with an antigenically new virus may be strongly reduced compared with younger vaccinees.
Similar articles
-
Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.J Med Virol. 2000 May;61(1):94-9. J Med Virol. 2000. PMID: 10745239
-
Vaccination-induced HI antibody response to intraepidemic influenza A(H3N2) virus variants of the 1996-1997 epidemic season.J Med Virol. 2001 Nov;65(3):584-9. J Med Virol. 2001. PMID: 11596097
-
Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.Virus Res. 2004 Jul;103(1-2):91-5. doi: 10.1016/j.virusres.2004.02.019. Virus Res. 2004. PMID: 15163495
-
Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.Jpn J Infect Dis. 2005 Aug;58(4):195-207. Jpn J Infect Dis. 2005. PMID: 16116250 Review.
-
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Vaccines (Basel). 2014 Oct 13;2(4):707-34. doi: 10.3390/vaccines2040707. Vaccines (Basel). 2014. PMID: 26344888 Free PMC article. Review.
Cited by
-
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.Mol Ther. 2022 May 4;30(5):2024-2047. doi: 10.1016/j.ymthe.2022.01.011. Epub 2022 Jan 7. Mol Ther. 2022. PMID: 34999208 Free PMC article.
-
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.J Immunol. 2011 May 15;186(10):6044-55. doi: 10.4049/jimmunol.1004095. Epub 2011 Apr 15. J Immunol. 2011. PMID: 21498665 Free PMC article.
-
Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.Clin Vaccine Immunol. 2016 Jan 13;23(3):228-35. doi: 10.1128/CVI.00604-15. Clin Vaccine Immunol. 2016. PMID: 26762363 Free PMC article. Clinical Trial.
-
Measuring Vaccine Responses in the Multiplex Era.Methods Mol Biol. 2025;2868:149-162. doi: 10.1007/978-1-0716-4200-9_9. Methods Mol Biol. 2025. PMID: 39546230
-
Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).Vaccine. 2015 Jul 9;33(30):3562-70. doi: 10.1016/j.vaccine.2015.05.049. Epub 2015 Jun 1. Vaccine. 2015. PMID: 26044496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources